These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 34659239)
1. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H Front Immunol; 2021; 12():743422. PubMed ID: 34659239 [TBL] [Abstract][Full Text] [Related]
2. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
3. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related]
4. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G Front Immunol; 2021; 12():737083. PubMed ID: 34539673 [TBL] [Abstract][Full Text] [Related]
5. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205 [TBL] [Abstract][Full Text] [Related]
6. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5. Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903 [TBL] [Abstract][Full Text] [Related]
7. BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Jahrsdörfer B; Proffen M; Scholz J; Hägele J; Ludwig C; Vieweg C; Grempels A; Fabricius D; Lotfi R; Körper S; Adler G; Schrezenmeier H Front Immunol; 2022; 13():920210. PubMed ID: 35795665 [TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170 [TBL] [Abstract][Full Text] [Related]
10. Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4 Meyer-Arndt L; Schwarz T; Loyal L; Henze L; Kruse B; Dingeldey M; Gürcan K; Uyar-Aydin Z; Müller MA; Drosten C; Paul F; Sander LE; Demuth I; Lauster R; Giesecke-Thiel C; Braun J; Corman VM; Thiel A J Immunol; 2022 Mar; 208(5):1001-1005. PubMed ID: 35121642 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006 [TBL] [Abstract][Full Text] [Related]
12. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
13. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD; Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays. Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H Front Immunol; 2023; 14():1170759. PubMed ID: 37180152 [TBL] [Abstract][Full Text] [Related]
15. Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2. Lee B; Bae GE; Jeong IH; Kim JH; Kwon MJ; Kim J; Kim B; Lee JW; Nam JH; Huh HJ; Kang ES J Appl Lab Med; 2024 Jul; 9(4):741-751. PubMed ID: 38531067 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L Front Immunol; 2022; 13():829665. PubMed ID: 35154152 [TBL] [Abstract][Full Text] [Related]
18. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
19. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181 [TBL] [Abstract][Full Text] [Related]
20. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]